GT201400085A - Profármaco de adrenomedulina basado en polietilenglicol y su uso - Google Patents

Profármaco de adrenomedulina basado en polietilenglicol y su uso

Info

Publication number
GT201400085A
GT201400085A GT201400085A GT201400085A GT201400085A GT 201400085 A GT201400085 A GT 201400085A GT 201400085 A GT201400085 A GT 201400085A GT 201400085 A GT201400085 A GT 201400085A GT 201400085 A GT201400085 A GT 201400085A
Authority
GT
Guatemala
Prior art keywords
adrenomeduline
polyethylene glycol
promote based
diseases
prevention
Prior art date
Application number
GT201400085A
Other languages
English (en)
Spanish (es)
Inventor
Flamme Ingo
Köbberling Johannes
Lerchen Hans-Georg
Griebenow Nils
Schohe-Loop Rudolf
Wittrock Sven
Köllnberger Maria
Wunder Frank
Redlich Gorden
Knorr Andreas
Marley July
Pritchard Iain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201400085A publication Critical patent/GT201400085A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
GT201400085A 2011-11-03 2014-04-30 Profármaco de adrenomedulina basado en polietilenglicol y su uso GT201400085A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03

Publications (1)

Publication Number Publication Date
GT201400085A true GT201400085A (es) 2015-03-05

Family

ID=47146369

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400085A GT201400085A (es) 2011-11-03 2014-04-30 Profármaco de adrenomedulina basado en polietilenglicol y su uso

Country Status (45)

Country Link
US (3) US9603936B2 (enExample)
EP (2) EP2773376B1 (enExample)
JP (2) JP5995984B2 (enExample)
KR (2) KR102004668B1 (enExample)
CN (2) CN103998063B (enExample)
AR (2) AR088582A1 (enExample)
AU (2) AU2012331244B2 (enExample)
BR (1) BR112014010708B1 (enExample)
CA (1) CA2854134C (enExample)
CL (1) CL2014000948A1 (enExample)
CO (1) CO7020863A2 (enExample)
CR (1) CR20140184A (enExample)
CU (1) CU24184B1 (enExample)
CY (2) CY1117354T1 (enExample)
DK (2) DK3075395T3 (enExample)
DO (2) DOP2014000078A (enExample)
EA (2) EA029410B1 (enExample)
EC (2) ECSP14013326A (enExample)
ES (2) ES2568063T3 (enExample)
GT (1) GT201400085A (enExample)
HR (2) HRP20160285T1 (enExample)
HU (2) HUE027333T2 (enExample)
IL (3) IL232037B (enExample)
IN (1) IN2014CN03290A (enExample)
JO (2) JOP20190001B1 (enExample)
LT (1) LT3075395T (enExample)
MA (1) MA35618B1 (enExample)
ME (1) ME02379B (enExample)
MX (2) MX350341B (enExample)
MY (2) MY194197A (enExample)
NO (1) NO3075395T3 (enExample)
PE (2) PE20141219A1 (enExample)
PH (1) PH12014500998A1 (enExample)
PL (2) PL3075395T3 (enExample)
PT (1) PT3075395T (enExample)
RS (2) RS56819B1 (enExample)
SG (2) SG11201400924TA (enExample)
SI (2) SI2773376T1 (enExample)
TN (1) TN2014000185A1 (enExample)
TR (1) TR201802124T4 (enExample)
TW (2) TWI653051B (enExample)
UA (1) UA111098C2 (enExample)
UY (2) UY34419A (enExample)
WO (1) WO2013064508A1 (enExample)
ZA (1) ZA201600434B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012331279A1 (en) * 2011-11-03 2014-05-08 Bayer Intellectual Property Gmbh Tyrosine based linkers for the releasable connection of peptides
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
US11414474B2 (en) 2014-03-20 2022-08-16 University Of Miyazaki Long-acting adrenomedullin derivatives
WO2016046301A1 (en) * 2014-09-26 2016-03-31 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
KR102152437B1 (ko) * 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 장시간 작용형 아드레노메둘린 유도체
JP7001285B2 (ja) * 2017-03-29 2022-01-19 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2020254197A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
KR20220093106A (ko) * 2019-09-21 2022-07-05 익사카 프랑스 올리고펩티드-변형된 폴리(베타-아미노 에스테르)의 무-dmso 합성 및 나노입자 전달 시스템에서의 이의 용도
JP7498882B2 (ja) * 2019-12-05 2024-06-13 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
AU2021247501A1 (en) 2020-04-03 2022-10-27 Bayer Aktiengesellschaft Pharmaceutical formulations polyethylene glycol-based prodrugs of Adrenomedullin and use
IL296972A (en) * 2020-04-03 2022-12-01 Bayer Ag Liquid pharmaceutical formulations of polyethylene glycol-based drug excipients of adrenomedullin and use
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
IL310248A (en) 2021-08-20 2024-03-01 Bayer Ag Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
WO2025133215A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Use of inactive adrenomedullin precursor for therapeutic purposes
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
PT1646813E (pt) 2003-07-23 2013-07-09 Ppg Ind Ohio Inc Vedante compósito e conjunto de janela
JP4950022B2 (ja) 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
DK1749026T3 (da) 2004-05-24 2012-02-27 Inst Cardiologie Montreal Mærkede adrenomedullinderivater og deres anvendelse til billeddannelse og terapi
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2008075968A1 (en) * 2006-12-20 2008-06-26 Ge Healthcare As Contrast agents
DK2155781T3 (da) 2007-05-11 2013-06-17 Inst Cardiologie Montreal Mærkede adrenomedullinderivater og deres anvendelse til visualisering og terapi
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
AU2012331279A1 (en) * 2011-11-03 2014-05-08 Bayer Intellectual Property Gmbh Tyrosine based linkers for the releasable connection of peptides

Also Published As

Publication number Publication date
LT3075395T (lt) 2018-02-26
CA2854134C (en) 2020-04-21
MA35618B1 (fr) 2014-11-01
IL258229A (en) 2018-06-28
UY37922A (es) 2018-11-30
CN107412740B (zh) 2021-02-09
TW201720467A (zh) 2017-06-16
IL232037B (en) 2018-12-31
HK1246147A1 (zh) 2018-09-07
CR20140184A (es) 2014-05-27
DOP2018000203A (es) 2018-10-15
ES2568063T3 (es) 2016-04-27
SI2773376T1 (sl) 2016-05-31
JP6177975B2 (ja) 2017-08-09
JOP20190001B1 (ar) 2022-03-14
EP2773376B1 (en) 2016-01-13
EA201400528A1 (ru) 2014-10-30
CN107412740A (zh) 2017-12-01
DK3075395T3 (en) 2018-02-19
CN103998063B (zh) 2016-09-21
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
WO2013064508A1 (en) 2013-05-10
PL3075395T3 (pl) 2018-04-30
KR20180108892A (ko) 2018-10-04
EA201600495A1 (ru) 2016-10-31
AR113830A2 (es) 2020-06-17
CU20140051A7 (es) 2014-10-02
JOP20190001A1 (ar) 2017-06-16
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
AU2012331244A1 (en) 2014-04-17
MX2014004384A (es) 2014-04-30
NO3075395T3 (enExample) 2018-04-21
US9603936B2 (en) 2017-03-28
US20160367636A1 (en) 2016-12-22
US9649363B2 (en) 2017-05-16
ES2659195T3 (es) 2018-03-14
AU2017203423A1 (en) 2017-06-08
EP2773376A1 (en) 2014-09-10
CU24184B1 (es) 2016-07-29
IL232037A0 (en) 2014-05-28
MY194197A (en) 2022-11-21
CA2854134A1 (en) 2013-05-10
RS56819B1 (sr) 2018-04-30
CY1117354T1 (el) 2017-04-26
US10035818B2 (en) 2018-07-31
TWI653051B (zh) 2019-03-11
EA029410B1 (ru) 2018-03-30
CL2014000948A1 (es) 2014-09-05
DK2773376T3 (en) 2016-04-18
MX350341B (es) 2017-09-04
KR102004668B1 (ko) 2019-07-26
EA025631B1 (ru) 2017-01-30
IL258229B (en) 2020-02-27
NZ714621A (en) 2017-10-27
JP2014532682A (ja) 2014-12-08
TWI583396B (zh) 2017-05-21
TR201802124T4 (tr) 2018-03-21
JO3385B1 (ar) 2019-03-13
AU2012331244B2 (en) 2017-06-15
PH12014500998A1 (en) 2014-06-09
CO7020863A2 (es) 2014-08-11
UA111098C2 (uk) 2016-03-25
PT3075395T (pt) 2018-02-13
BR112014010708A2 (pt) 2017-04-25
PL2773376T3 (pl) 2016-07-29
IL252281A0 (en) 2017-08-31
ECSP18071104A (es) 2018-10-31
SI3075395T1 (en) 2018-03-30
PE20181493A1 (es) 2018-09-18
ECSP14013326A (es) 2014-05-31
PE20141219A1 (es) 2014-09-13
JP2017014264A (ja) 2017-01-19
IN2014CN03290A (enExample) 2015-07-03
MY173372A (en) 2020-01-21
AU2017203423B2 (en) 2019-01-31
EP3075395B1 (en) 2017-11-22
JP5995984B2 (ja) 2016-09-21
SG11201400924TA (en) 2014-09-26
ZA201600434B (en) 2017-05-31
KR101965467B1 (ko) 2019-04-03
NZ622997A (en) 2015-12-24
SG10201607516SA (en) 2016-10-28
CN103998063A (zh) 2014-08-20
DOP2014000078A (es) 2014-07-15
EP3075395A1 (en) 2016-10-05
CY1119897T1 (el) 2018-06-27
HRP20180319T1 (hr) 2018-03-23
HUE027333T2 (en) 2016-09-28
RS54623B1 (sr) 2016-08-31
US20140287984A1 (en) 2014-09-25
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
US20170204137A1 (en) 2017-07-20
AR088582A1 (es) 2014-06-18
HUE036535T2 (hu) 2018-07-30
TW201332573A (zh) 2013-08-16
BR112014010708B1 (pt) 2021-03-02
UY34419A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2015003140A (es) Formulaciones de enzalutamida.
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2014001399A1 (es) Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion.
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
UY35747A (es) Derivados sustituidos de fenilalanina
UY35746A (es) Derivados de fenilalanina sustituidos
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY35745A (es) Derivados sustituidos de fenilalanina
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2015000290A (es) Benzoxazoles sustituidos
TH148806B (th) สูตรผสมทางเภสัชกรรมที่มีความคงตัวดีขึ้น
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina